Inactive Ingredient Search for Approved Drug Products
You are Searching: Change and Deletion by Inactive Ingredient Name Beginning with P
| Quarter | Inactive Ingredient | Route of Administration | Dosage Form | Maximum Potency per unit dose | Maximum Daily Exposure | Status | |
|---|---|---|---|---|---|---|---|
| Q2 2024 | PEG-100 STEARATE | TOPICAL | CREAM | 552mg | Correction | ||
| Q3 2024 | PEG-100 MONOSTEARATE | TOPICAL | CREAM | 552mg | Correction | ||
| Q2 2024 | PEG-100 STEARATE | TOPICAL | CREAM, AUGMENTED | 0.50 %w/w | Correction | ||
| Q3 2024 | PEG-100 MONOSTEARATE | TOPICAL | CREAM, AUGMENTED | 0.50 %w/w | Correction | ||
| Q2 2024 | PEG-100 STEARATE | TOPICAL | LOTION | 1.00 %w/w | Correction | ||
| Q3 2024 | PEG-100 MONOSTEARATE | TOPICAL | LOTION | 1.00 %w/w | Correction | ||
| Q2 2024 | PEG-100 STEARATE | VAGINAL | CREAM | NA | Correction | ||
| Q3 2024 | PEG-100 MONOSTEARATE | VAGINAL | CREAM | 100mg | Correction | ||
| Q2 2024 | PEG-8 STEARATE | ORAL | CONCENTRATE | 25.00 mg/ 5.00 ml | Correction | ||
| Q3 2024 | PEG-8 MONOSTEARATE | ORAL | CONCENTRATE | 25.00 mg/ 5.00 ml | Correction | ||
| Q2 2024 | PEG-8 STEARATE | ORAL | SUSPENSION | 60mg | Correction | ||
| Q3 2024 | PEG-8 MONOSTEARATE | ORAL | SUSPENSION | 60mg | Correction | ||
| Q2 2024 | PEG-8 STEARATE | TOPICAL | CREAM | 229mg | Correction | ||
| Q3 2024 | PEG-8 MONOSTEARATE | TOPICAL | CREAM | 229mg | Correction | ||
| Q2 2024 | PEG-8 STEARATE | TOPICAL | SPONGE | NA | Correction | ||
| Q3 2024 | PEG-8 MONOSTEARATE | TOPICAL | SPONGE | NA | Correction | ||
| Q2 2024 | POLYDEXTROSE | ORAL | TABLET | 22mg | Correction | ||
| Q3 2024 | POLYDEXTROSE | ORAL | TABLET | 20mg | Correction | ||
| Q2 2024 | POLYETHYLENE GLYCOL 3350 | ORAL | TABLET, ORALLY DISINTEGRATING | 0.09 mg | Correction | ||
| Q3 2024 | POLYETHYLENE GLYCOL 3350 | ORAL | TABLET, ORALLY DISINTEGRATING | 0.08 mg | Correction | ||
| Q2 2024 | POLYOXYL 40 STEARATE | AURICULAR (OTIC) | SUSPENSION | 1.00 %w/v | Correction | ||
| Q3 2024 | POLYOXYL 40 STEARATE TYPE I | AURICULAR (OTIC) | SUSPENSION | 1.00 %w/v | Correction | ||
| Q2 2024 | POLYOXYL 40 STEARATE | OPHTHALMIC | OINTMENT | NA | Correction | ||
| Q3 2024 | POLYOXYL 40 STEARATE TYPE I | OPHTHALMIC | OINTMENT | NA | Correction | ||
| Q2 2024 | POLYOXYL 40 STEARATE | OPHTHALMIC | SOLUTION | 7.00 %w/w | Correction | ||
| Q3 2024 | POLYOXYL 40 STEARATE TYPE I | OPHTHALMIC | SOLUTION | 7.00 %w/w | Correction | ||
| Q2 2024 | POLYOXYL 40 STEARATE | OPHTHALMIC | SUSPENSION | 0.50 %w/v | Correction | ||
| Q3 2024 | POLYOXYL 40 STEARATE TYPE I | OPHTHALMIC | SUSPENSION | 0.50 %w/v | Correction | ||
| Q2 2024 | POLYOXYL 40 STEARATE | ORAL | CAPSULE | 7.00 mg | Correction | ||
| Q3 2024 | POLYOXYL 40 STEARATE TYPE I | ORAL | CAPSULE | 7mg | Correction | ||
| Q2 2024 | POLYOXYL 40 STEARATE | ORAL | GRANULE | NA | Correction | ||
| Q3 2024 | POLYOXYL 40 STEARATE TYPE I | ORAL | GRANULE | NA | Correction | ||
| Q2 2024 | POLYOXYL 40 STEARATE | ORAL | TABLET | 8.48 mg | Correction | ||
| Q3 2024 | POLYOXYL 40 STEARATE TYPE I | ORAL | TABLET | 8.48 mg | Correction | ||
| Q2 2024 | POLYOXYL 40 STEARATE | ORAL | TABLET, FILM COATED | 2.00 mg | Correction | ||
| Q3 2024 | POLYOXYL 40 STEARATE TYPE I | ORAL | TABLET, FILM COATED | 2.00 mg | Correction | ||
| Q2 2024 | POLYOXYL 40 STEARATE | TOPICAL | AEROSOL, FOAM | 2.83 %w/w | Correction | ||
| Q3 2024 | POLYOXYL 40 STEARATE TYPE I | TOPICAL | AEROSOL, FOAM | 2.83 %w/w | Correction | ||
| Q2 2024 | POLYOXYL 40 STEARATE | TOPICAL | CREAM | 8.80 %w/w | Correction | ||
| Q3 2024 | POLYOXYL 40 STEARATE TYPE I | TOPICAL | CREAM | 50mg | Correction | ||
| Q2 2024 | POLYOXYL 40 STEARATE | TOPICAL | LOTION | 3.00 %w/w | Correction | ||
| Q3 2024 | POLYOXYL 40 STEARATE TYPE I | TOPICAL | LOTION | 3.00 %w/w | Correction | ||
| Q2 2024 | POLYOXYL 40 STEARATE | TOPICAL | OINTMENT | NA | Correction | ||
| Q3 2024 | POLYOXYL 40 STEARATE TYPE I | TOPICAL | OINTMENT | NA | Correction | ||
| Q2 2024 | POLYOXYL 40 STEARATE | TOPICAL | SPONGE | NA | Correction | ||
| Q3 2024 | POLYOXYL 40 STEARATE TYPE I | TOPICAL | SPONGE | NA | Correction | ||
| Q2 2024 | PROSOLV 50 | ORAL | CAPSULE | 33mg | Correction | ||
| Q2 2024 | PROSOLV 50 | ORAL | CAPSULE, EXTENDED RELEASE | 440mg | Correction | ||
| Q2 2024 | PROSOLV 50 | ORAL | TABLET | 203.40 mg | Correction | ||
| Q2 2024 | PROSOLV 50 | ORAL | TABLET, EXTENDED RELEASE | 315.00 mg | Correction | ||
| Q2 2024 | PROSOLV 90 | ORAL | CAPSULE | 50mg | Correction | ||
| Q2 2024 | PROSOLV 90 | ORAL | TABLET | 702mg | Correction | ||
| Q2 2024 | PROSOLV 90 | ORAL | TABLET, EXTENDED RELEASE | 25.00 mg | Correction | ||
| Q2 2024 | PROSOLV 90 | SUBLINGUAL | TABLET | 19mg | Correction | ||
| Q2 2024 | PROSOLV SMCC 50 | ORAL | CAPSULE | 355mg | Correction | ||
| Q2 2024 | PROSOLV SMCC 50 | ORAL | TABLET | 1889mg | Correction | ||
| Q2 2024 | PROSOLV SMCC 50 | ORAL | TABLET, EXTENDED RELEASE | 648mg | Correction | ||
| Q2 2024 | PROSOLV SMCC 50 | ORAL | TABLET, FILM COATED | 100mg | Correction | ||
| Q2 2024 | PROSOLV SMCC 90 | ORAL | CAPSULE | 283mg | Correction | ||
| Q2 2024 | PROSOLV SMCC 90 | ORAL | CAPSULE, EXTENDED RELEASE | 18mg | Correction | ||
| Q2 2024 | PROSOLV SMCC 90 | ORAL | TABLET | 1136mg | Correction | ||
| Q2 2024 | PROSOLV SMCC 90 | ORAL | TABLET, CHEWABLE | 28mg | Correction | ||
| Q2 2024 | PROSOLV SMCC 90 | ORAL | TABLET, DELAYED RELEASE | 159mg | Correction | ||
| Q2 2024 | PROSOLV SMCC 90 | ORAL | TABLET, EXTENDED RELEASE | 1073mg | Correction | ||
| Q2 2024 | PROSOLV SMCC 90 | ORAL | TABLET, FILM COATED | 183mg | Correction | ||
| Q2 2024 | PROSOLV SMCC 90 | ORAL | TABLET, ORALLY DISINTEGRATING | 70mg | Correction | ||
| Q2 2024 | PROSOLV SMCC HD 90 | ORAL | CAPSULE | 1600mg | Correction | ||
| Q2 2024 | PROSOLV SMCC HD 90 | ORAL | CAPSULE, DELAYED RELEASE | 304mg | Correction | ||
| Q2 2024 | PROSOLV SMCC HD 90 | ORAL | TABLET | 1054mg | Correction | ||
| Q2 2024 | PROSOLV SMCC HD 90 | ORAL | TABLET, DELAYED RELEASE | 764mg | Correction | ||
| Q2 2024 | PROSOLV SMCC HD 90 | ORAL | TABLET, EXTENDED RELEASE | 1029mg | Correction | ||
| Q2 2024 | PROSOLV SMCC HD 90 | ORAL | TABLET, FILM COATED | 376mg | Correction | ||
| Q2 2024 | PROSOLV SMCC HD 90 | ORAL | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE | 226mg | Correction | ||
| Q3 2024 | POLYGLYCERYL-3 OLEATE | ORAL | CAPSULE, GELATIN COATED | 0.87 mg | 1mg | Deletion | |
| Q3 2024 | POLYSORBATE 80 | INTRABURSAL | INJECTION | 0.04 %w/v | Deletion | ||
| Q3 2024 | POLYSTYRENE SULFONIC ACID | ORAL | TABLET, EXTENDED RELEASE | 43.15 mg | 89mg | Deletion | |
| Q3 2024 | POVIDONE K30 | ORAL | CAPSULE, GELATIN COATED | 21.00 mg | 21mg | Deletion | |
| Q2 2024 | PEG-100 STEARATE | VAGINAL | CREAM | NA | MDE Replacement | ||
| Q3 2024 | PEG-100 MONOSTEARATE | VAGINAL | CREAM | 100mg | MDE Replacement | ||
| Q2 2024 | PEPPERMINT OIL | ORAL | SOLUTION | 3.50 mg/ 1.00 ml | MDE Replacement | ||
| Q3 2024 | PEPPERMINT OIL | ORAL | SOLUTION | 16mg | MDE Replacement | ||
| Q2 2024 | POLYETHYLENE GLYCOL 400 | ORAL | CONCENTRATE | 600.00 mg/ 1.00 ml | MDE Replacement | ||
| Q3 2024 | POLYETHYLENE GLYCOL 400 | ORAL | CONCENTRATE | 3000mg | MDE Replacement | ||
| Q2 2024 | POLYGLYCERYL-3 OLEATE | VAGINAL | CREAM | 2.70 %w/w | MDE Replacement | ||
| Q3 2024 | POLYGLYCERYL-3 OLEATE | VAGINAL | CREAM | 135mg | MDE Replacement | ||
| Q2 2024 | POLYOXYL 40 STEARATE | ORAL | CAPSULE | 7.00 mg | MDE Replacement | ||
| Q3 2024 | POLYOXYL 40 STEARATE TYPE I | ORAL | CAPSULE | 7mg | MDE Replacement | ||
| Q2 2024 | POLYOXYL 40 STEARATE | TOPICAL | CREAM | 8.80 %w/w | MDE Replacement | ||
| Q3 2024 | POLYOXYL 40 STEARATE TYPE I | TOPICAL | CREAM | 50mg | MDE Replacement | ||
| Q2 2024 | POLYSORBATE 20 | TOPICAL | LOTION | 7.80 %w/w | MDE Replacement | ||
| Q3 2024 | POLYSORBATE 20 | TOPICAL | LOTION | 2000mg | MDE Replacement | ||
| Q2 2024 | POTASSIUM SORBATE | TOPICAL | AEROSOL, FOAM | 0.20 %w/w | MDE Replacement | ||
| Q3 2024 | POTASSIUM SORBATE | TOPICAL | AEROSOL, FOAM | 8mg | MDE Replacement | ||
| Q2 2024 | POVIDONE K12 | INTRAVENOUS | INJECTION | 20.00 mg | MDE Replacement | ||
| Q3 2024 | POVIDONE K12 | INTRAVENOUS | INJECTION | 648mg | MDE Replacement | ||
| Q2 2024 | POVIDONE K30 | OPHTHALMIC | SUSPENSION | 0.60 %w/v | MDE Replacement | ||
| Q3 2024 | POVIDONE K30 | OPHTHALMIC | SUSPENSION | 14mg | MDE Replacement | ||
| Q2 2024 | POWDERED CELLULOSE | ORAL | CAPSULE | 405.00 mg | MDE Replacement | ||
| Q3 2024 | POWDERED CELLULOSE | ORAL | CAPSULE | 2430mg | MDE Replacement | ||
| Q2 2024 | PROPYLENE GLYCOL | TOPICAL | OINTMENT, AUGMENTED | 65.00 %w/w | MDE Replacement | ||
| Q3 2024 | PROPYLENE GLYCOL | TOPICAL | OINTMENT, AUGMENTED | 714mg | MDE Replacement | ||
| Q2 2024 | PROPYLENE GLYCOL MONOPALMITOSTEARATE | TOPICAL | OINTMENT, AUGMENTED | 2.00 %w/w | MDE Replacement | ||
| Q3 2024 | PROPYLENE GLYCOL MONOPALMITOSTEARATE | TOPICAL | OINTMENT, AUGMENTED | 143mg | MDE Replacement |
FDA/Center for Drug Evaluation and Research
Office of Pharmaceutical Quality
Office of Policy for Pharmaceutical Quality
Mailbox for IID corrections: IIDUpdate@fda.hhs.gov
Update Frequency: Quarterly
Data Through: July 3, 2024
Database Last Updated: July 31, 2024